<DOC>
	<DOCNO>NCT02177422</DOCNO>
	<brief_summary>The primary objective trial ass efficacy safety telmisartan 80 mg open-label , long-term treatment . An additional objective ass efficacy safety concomitant administration telmisartan 80 mg HCTZ ( Hydrochlorothiazide ) and/or therapy commonly use treatment hypertension .</brief_summary>
	<brief_title>Efficacy Safety Chronic Administration Telmisartan Monotherapy Combination With Hydrochlorothiazide Other Antihypertensive Medications Patients With Mild Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients meet inclusion criterion precede clinical trial telmisartan . All patient must give separate write informed consent participation openlabel followup . Mildtomoderate essential hypertension define mean seat diastolic blood pressure measurement ≥ 95 mmHg measure manual cuff sphygmomanometer Mean seat systolic blood pressure ≥ 140 mmHg , measure manual cuff A 24hour mean diastolic blood pressure , measure ABPM ( ambulatory blood pressure measurement ) , ≥ 85 mmHg Age 18 old Patient 's write informed consent accordance GCP ( Good Clinical Practice ) local legislation Patients clinically significant change ECG baseline report adverse event precede clinical trial Patients develop medical condition precede clinical trial , investigator 's opinion , may worsen treatment may compromise safety evaluation telmisartan Patients discontinue precede telmisartan clinical trial due adverse event Any clinical condition , opinion investigator , would allow safe completion protocol safe administration telmisartan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>